Search
Search
Leinco Technologies
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Specificity: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Adalimumab. Clone D2E7 binds to soluble TNF- alpha, but not to TNF- beta (lymphotoxin). This product is for research use only.
Endotoxin Level: ≤ 1.0 EU/mg as determined by the LAL method. Purity: >95% by SDS Page; ≥98% monomer by analytical SEC.
Product Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing: To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling: Functional grade preclinical antibodies may be stored sterile as received at 2-8 C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80 C. Avoid Repeated Freeze Thaw Cycles.
This antibody has been tested in the following applications: Neutralization, Immunoprecipitation, Immunohistochemistry, Immunofluorescence, Functional Assay, Flow Cytometry, ELISA, Blocking.
Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNF alpha (tumor necrosis factor-alpha), and blocks its interaction with TNF alpha receptors, reducing the inflammatory response of autoimmune diseases.
仅用于科研。不用于诊断过程。未经明确授权不得转售。